Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1

Learn more about:
Related Clinical Trial
DMCRN-02-001: Assessing Pediatric Endpoints in DM1 Myotonic Dystrophy Type 1 and Resistance Exercise Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients Biomarker Development for Muscular Dystrophies Extracellular RNA Biomarkers of Myotonic Dystrophy Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1 Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1 Myotonic Dystrophy – Vascular and Cognition Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 Open Label Study in Adolescents and Children With Myotonic Disorders European Home Mechanical Ventilation Registry Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ? Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1 Efficacy and Safety of DHEA for Myotonic Dystrophy Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1 Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 DM-IMT – Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1 Venous Thromboembolism in DM1 Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study) Children’s Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Observational Prolonged Trial in Myotonic Dystrophy Type 1 Venous Thromboembolism in Myotonic Dystrophy Type 1 Myotonic Dystrophy Type 1 Aerobic Exercise Study Multicenter Observational Study of Myotonic Dystrophy Type 1 DM1 Heart Registry – DM1 Respiratory Registry

Brief Title

Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1

Official Title

Double-Blind, Placebo-Controlled, Dose-Range-Finding, Crossover Trial of Single Day Administration of ERX-963 in Adults With Myotonic Dystrophy Type 1

Brief Summary

      Participants in this study will receive two treatments, placebo and ERX-963, on different
      days in a randomized fashion.

      The primary purpose of this study is to investigate the safety and tolerability of ERX-963 in
      participants diagnosed with Myotonic Dystrophy, Type 1 (DM1).

      The secondary purpose is to evaluate the potential of ERX-963 treatment to reduce excessive
      daytime sleepiness / hypersomnia and improve cognitive function in DM1 participants compared
      to placebo treatment.
    

Detailed Description

      This study is evaluating single administration of two dose levels of ERX-963 to explore the
      relationship between dose, safety, tolerability, exposure and clinical benefit. This is a
      multi-center, randomized, double-blind, placebo-controlled, two-treatment period crossover
      study in two cohorts of participants with DM1.

      Participants who have consented and meet eligibility criteria will receive two treatments,
      placebo and ERX-963, in a randomized crossover fashion with a washout period between the
      treatments. On treatment days, participants will receive treatment followed by repeated blood
      collection for pharmacokinetic analysis and administration of a battery of outcome measures
      relevant to sleep and cognition.
    

Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

Incidence of Adverse Events, Serious Adverse Events, and Drug-related Adverse Events [Safety and Tolerability] After a Single Dose of ERX-963 vs. Placebo

Secondary Outcome

 Assess the Effect of ERX-963 on the Stanford Sleepiness Scale Score Compared to the Effect of Placebo

Condition

Myotonic Dystrophy, Type 1 (DM1)

Intervention

ERX-963

Study Arms / Comparison Groups

 ERX-963 then placebo
Description:  Participants in this arm will receive ERX-963 followed by a washout period. After the washout period, participants will receive placebo.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

12

Start Date

June 17, 2019

Completion Date

April 30, 2020

Primary Completion Date

March 31, 2020

Eligibility Criteria

        Key Inclusion Criteria:

          -  18 to 65 years of age

          -  DM1 defined by genetic testing or clinical-confirmation

          -  Epworth Sleepiness Scale (ESS) of > 11 or participants who have long sleep periods of
             an average of > 10 hours a day

          -  Age of onset of DM1 greater than 16 years

        Key Exclusion Criteria:

          -  Significant respiratory compromise

          -  Significant cardiac disease

          -  Diagnosis of symptomatic Restless Leg Syndrome or significant untreated nocturnal
             hypoxias

          -  Significant moderate to severe hepatic insufficiency

          -  Clinically active depression, anxiety, or other medical condition that, in the
             investigator's opinion, would interfere with the safety and efficacy assessments

          -  History of seizures

          -  History of panic disorders
      

Gender

All

Ages

18 Years - 65 Years

Accepts Healthy Volunteers

No

Contacts

Elliot Ehrich, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03959189

Organization ID

ERX-963-001


Responsible Party

Sponsor

Study Sponsor

Expansion Therapeutics, Inc.


Study Sponsor

Elliot Ehrich, MD, Study Director, Chief Medical Officer


Verification Date

May 2021